TY - JOUR
T1 - Screening for Breast Cancer
T2 - US Preventive Services Task Force Recommendation Statement
AU - Nicholson, Wanda K.
AU - Silverstein, Michael
AU - Wong, John B.
AU - Barry, Michael J.
AU - Chelmow, David
AU - Coker, Tumaini Rucker
AU - Davis, Esa M.
AU - Jaén, Carlos Roberto
AU - Krousel-Wood, Marie
AU - Lee, Sei
AU - Li, Li
AU - Mangione, Carol M.
AU - Rao, Goutham
AU - Ruiz, John M.
AU - Stevermer, James J.
AU - Tsevat, Joel
AU - Underwood, Sandra Millon
AU - Wiehe, Sarah
N1 - Publisher Copyright:
© 2024 American Medical Association. All rights reserved.
PY - 2024/6/11
Y1 - 2024/6/11
N2 - Importance: Among all US women, breast cancer is the second most common cancer and the second most common cause of cancer death. In 2023, an estimated 43170 women died of breast cancer. Non-Hispanic White women have the highest incidence of breast cancer and non-Hispanic Black women have the highest mortality rate. Objective: The USPSTF commissioned a systematic review to evaluate the comparative effectiveness of different mammography-based breast cancer screening strategies by age to start and stop screening, screening interval, modality, use of supplemental imaging, or personalization of screening for breast cancer on the incidence of and progression to advanced breast cancer, breast cancer morbidity, and breast cancer-specific or all-cause mortality, and collaborative modeling studies to complement the evidence from the review. Population: Cisgender women and all other persons assigned female at birth aged 40 years or older at average risk of breast cancer. Evidence Assessment: The USPSTF concludes with moderate certainty that biennial screening mammography in women aged 40 to 74 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening mammography in women 75 years or older and the balance of benefits and harms of supplemental screening for breast cancer with breast ultrasound or magnetic resonance imaging (MRI), regardless of breast density. Recommendation: The USPSTF recommends biennial screening mammography for women aged 40 to 74 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women 75 years or older. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of supplemental screening for breast cancer using breast ultrasonography or MRI in women identified to have dense breasts on an otherwise negative screening mammogram. (I statement).
AB - Importance: Among all US women, breast cancer is the second most common cancer and the second most common cause of cancer death. In 2023, an estimated 43170 women died of breast cancer. Non-Hispanic White women have the highest incidence of breast cancer and non-Hispanic Black women have the highest mortality rate. Objective: The USPSTF commissioned a systematic review to evaluate the comparative effectiveness of different mammography-based breast cancer screening strategies by age to start and stop screening, screening interval, modality, use of supplemental imaging, or personalization of screening for breast cancer on the incidence of and progression to advanced breast cancer, breast cancer morbidity, and breast cancer-specific or all-cause mortality, and collaborative modeling studies to complement the evidence from the review. Population: Cisgender women and all other persons assigned female at birth aged 40 years or older at average risk of breast cancer. Evidence Assessment: The USPSTF concludes with moderate certainty that biennial screening mammography in women aged 40 to 74 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening mammography in women 75 years or older and the balance of benefits and harms of supplemental screening for breast cancer with breast ultrasound or magnetic resonance imaging (MRI), regardless of breast density. Recommendation: The USPSTF recommends biennial screening mammography for women aged 40 to 74 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women 75 years or older. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of supplemental screening for breast cancer using breast ultrasonography or MRI in women identified to have dense breasts on an otherwise negative screening mammogram. (I statement).
UR - http://www.scopus.com/inward/record.url?scp=85191808934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85191808934&partnerID=8YFLogxK
U2 - 10.1001/jama.2024.5534
DO - 10.1001/jama.2024.5534
M3 - Review article
C2 - 38687503
AN - SCOPUS:85191808934
SN - 0098-7484
VL - 331
SP - 1918
EP - 1930
JO - JAMA
JF - JAMA
IS - 22
ER -